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Blood concentrations of cyclosporine were determined in adult and pediatric patients 
foJlowing orthotopic liver transplantation to quantitate cyc10sparine blood clearance and 
oral absorption. Seventeen bioavailability studies were performed follOWing transplanta-
tion surgery in nine children and seven adults. The intravenous cycl08porine study was 
performed following an average dose of 2.1 mglkg. The patients were again studied when 
they received the same intravenous dose plus an oral dose of cycl08porine of 8.6 mg/kg or 
an oral dose alone. Blood samples were collected and analyzed for cycl08porine using 
high-performance liquid chromatography. Cycl08porine blood clearance ranged from 29 
to 203 mUmin (1.9-21.5 mUmin/kg) in children and from 253 to 680 mVmin (3.2-7.6 
mL/min/kg) in adults. The mean cyc1osporine clearance value was 9.3 mUminlkg in the 
pediatric patients and 5.5 mUminlkg in the adults. Cyciosporine bioovailability was less 
than 5% in six studies on (rve pediatric patients in the immediate postoperative period. 
The bioavailability varied from 8% to 60% in adult liver transplant patients [mean. 27%J. 
We conclude that: (1) cyclosporine clearance is highly variable between patients. (2) 
pediatric patients clear the drug more rapidly than adults and therefore need a higher 
cyclosporine dose on a body weight basis, {3} cyc1osporine is poorly and variably absorbed 
in liver transplant patients, and (4} cyclosporine blood concentration monitoring is 
essential following orthotopic liver transplantation. 
Orthotopic liver transplantation is now considered a 
therapeutic alternative for children with diseases such 
as biliary atresia and alphal-antitrypsin deftciency and for 
adults with primary biliary cirrhosis and sclerosing cholan-
gitis.1-S Therapy with cyclosporine and low-dose steroids 
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constitutes a major advance in the treatment of patients 
undergoing orthotopic liver transplantation.s 
Liver transplantation presents special problems in main-
taining adequate pharmacologic immunosuppression. The 
absorption, metabolism, and excretion of pharmacologic 
agents can be expected to be significantly altered by the 
transplantation procedure. Aggressive drug therapy is often 
needed to achieve adequate immunosuppression. 
Adequate blood concentrations of cyclosporine are main-
tained following orthotopic liver transplantation by pro-
longed intravenous (IV) and combined IV and oral therapy. 
This cyciosporine dosing regimen is different than that used 
following renal or heart transplantation and prompted us to 
Investigate the clearance and bioavailability of cyclosporine 
following orthotopic liver transplantation. 
PATIENTS AND METHODS 
All patients who underwent orthotopic liver transplantation 
were considered candidates for the study. Seventeen stud-
ies were performed after patient (seven adults) or parental 
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(nine children) consent was obtained. Fifteen patients 
received the same intravenous cyclosporine dosage every 
eight hours for at least 24 hours before the start of the 
study. 
Protocol 
On the first study day. the patients received their prescribed 
IV cyclosporine dosage infused over two hours by Harvard 
infusion pump (Bard Medical Systema. North Reading. MA) 
or an IV drip set. In the ten pediatric studies. heparinized 
blood samples were obtained before the start of the infu-
sion. at the end of the infusion. and at four. six, and eight 
hours following the start of the infusion. Hourly blood 
samples were coJIected during the dosing interval in adults. 
On the second study day. ten children and two· adults 
received the same IV dose of cyclosporine at the same time 
of the day. but also received an oral cycl08porine dose 
concurrent with the start of the infusion. Five adult patients 
received only oral cycJosporine q12h on the second day. 
The oral cyclosporine liquid was diluted with juice or 
cpocolate milk. ptixed. and administered as quickly as 
possible. The blood sampling on the second day ronowed 
the same schedule as that of the flrst day. with the exception 
that the adult patients were sampled hourly for 12 hours. 
Concurrent medications administered w!th cyclosporine 
included methylprednisolone or prednisone. cefotaxime 
and ampicillin. captropril. hydralazine.· furosemide. and 
nystatin. 
Blood samples were refrigerated at 4°C until assayed «7 
days). AJ1 extraction and a high-performance liquid chro-
matographiC assay similar to that of Sawcquk and Cartier 
was used7 The assays were performed using whole blood. 
and cycl08porin 0 was the internal standard; The drug was 
initially extracted Into diethyl ~therK After dryinS. the 
residue was taken up in me~nolK combined yvith hydro· 
chloric acid. and washed ~ce with h~neK After neutral· 
ization. the drug and internal standard were reextracted 
into ether. dried. and reconstituted with the mobile· phase 
before injection. The samples were injected onto a lS-em 
C-18 column (Supelco. Bellefonte. PAl maintained at 70°C. 
The mobile phase was 68"10 acetonitrile in water with a flow 
rate of 1.5 mLlJnin. lTltraviolet detection was achieved at 
214 nm with a Model 441 detector (Waters. Milford. MAJ. 
All samples and standards were analyzed in duplicate. The 
retention times for cyclosporine and cyclosporin D were 8.3 
and 11.2 minutes, respectively. 'The minimum detectable 
level of this assay is 25 ng/mL using one milliliter of blood. 
Standard curves were run (rom concentrations of 50-2.000 
ng/mL. The Interday coefftclent of variation of the assay 
was 8.0"1. at 250 ng/mL (N - 35). 6.4"1. at 500 ng/mL 
(N = 191. and 7.7% at 1,000 ng/mL [N = 23). 
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Data Analysis 
The short dosing interval precluded calculation of a half· 
life or elimination'rate constant. All studies were carried out 
at steady-state or pseudo-steady-state conditions. The area 
under the curve (AUG) for the blood concentration versus 
time curve was calculated by the trapezoidal rule over one 
dosing interval. Drug clearance was calculated as the IV 
cyclosporine dose divided by the A UC (IV) and bioavail. 
ability percentage (F) was calculated as: 
F AUC (IV + oral) - AUe (IV) dose (IV) 
- AUC (IV) X dose (oral) X 100 or 
F AUC (oral) dose (IV) 
- X X 100 AVC (IV) dose (oral) 
Rank correlation of subgroups were compared using the 
Wilcoxon two-tailed analysis assuming a level of signifi-
cance of P S .05. 
RESULTS 
The characteristics of the patients at the time of study are 
listed in Table 1. Patient 7 was studied twice after two 
separate transplant operations. Nine of the studies were 
performed after the first orthotopic liver transplantation. 
seven after the second. and one after the third operation. 
Nine of the studies were started on the second or third day 
postoperatively. 
The maximum blood concentration after the IV cycI08PO· 
rine was observed at the end of the infusion and the blood 
concentration declined in a biexponential fashion. Figures 1 
and 2 present the blood concentrauon versus time for a 
representative adult and pediatric:: patient. Table II lists the 
estimated pharmacokinetic parameters derived from the 
blood concentration versus time data. The average cyclo-
sporine dosage was 2.1 mg/kg IV and 8.6 mg/kg orally. The 
mean trough concen~tion at eight hours was 298 ng/mL 
following IV cyclosporine in the pediatric patients. Four of 
the pediatriC patients had a cyclosporine clearance of 
8l'eater than ~l mLlmin/kg. The clearance of cyclosporine 
in the "dull patients ranged from 3.2 to 7.6 mUmin/kg. The 
mean cyclosporine clearance WiS 9.3 mLlmin/kg in the 
pediatric population and 5.5 mL/min/kg 4t the adults. 
Six studies,Gonducted in the pediatric study pOPlliation in 
the immeqiate postoperative period demonstrated an esti-
mated bioavailabillty of less than 5"10 of the orally adminis-
tered cyclosporine. In these patients. cyc10sp0rine clear-
ance was less lhlln 10 mL/min/kg. The other four children 
with bioavailability greater than 50/. had cycloaporine blood 
clearances greater than 10 mLhnin/kg (p ... 01). A wide 
variatioJl in the' extent of absorption iii adult patients was 
observed as Indicated by a bioavallability of 8% to 6O"!o 
(mean ± standartl deviation - 27 ± 18"1.). The two adults 
with an 8% and 15'70 bioavailability had a serum bilirubin 
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qAU~1 
Patient ett_ractertstlCl 
PoItoperatiH Day Oft 
Which Study Wat Performed 
htlent All· We'.ht (11&) 0 .... '.,.. DIaP,oI'1 IV IY+ PO PO 
1 34 mo 11.4 Biliary atresia 2 3 
2 67 mo 16.8 ai-antitrypsin deficie!,!cy 8 9 
3 52 mo 12.3 Biliary atresia 3 4 
i5.5 4 39 mo Biliary atresia 3 4 
5 11 mo 8.2 Biliary atresia 2 3 
6 51 mo 17.9 Biliary atresia 3 4 
Hepatitis 7a 36 mo 15.3 3 4 
7b 37 mo 14.4 I-t!!patitis 2 3 
8 47 mo 14.3 Biliary atresia 2 3 
9 7 mo 7.0 Biliary atresia 2 3 
10 47 yr 52 Primary biliary cirrhosis 3 43 
11 21 yr 40 Tyrosinemia, hepatoma 2 24 
12 42 yr 88 Post-necrotic cirrhosis 18 29 
13 26 yr 70 Hepatitis, cirrhosis 5 56 
49 14 51 yr 55 ~rimary biliary cirrhosis 2 
15 27 yr 96 Post-necrotic cirrhosis 2 21 
16 36 yr 61 ChroniC active hepatitis 29 30 
IV '" intravenous: PO '" oral. 
concentration of greater than 2.0 mgldL, whereas the five 
adult patients with greater cycl08porine absorption had a 
serum. bilirubin of less than 2.0 mgldL. The serum bilirubin 
concentration was greater than 3.6 mgldL In all the pediat-
ric patients. 
DISCUSSION 
The phanna.cokinetics of cyclosporlne have been investi-
gated in the recipients of allogenic bone marrow grafts and 
transplanted kidneys and hearts. The harmonjc mean 
cycI08porine blood clearance in Jddney tianaplant recipi-
ents Is 5.7 IDLIminlkg (range. 0.6-23.9 mLlmin/kgl.' The 
plasma clearance of the drug was previously determined to 
be 12.2 ± 5.6 mUmin/lcg in bone Marrow transplant 
patients.9 wheO}as the blood clearance ran8ed fro!D 2.1 to 
15.1 mLiminlkg in patients receiving heart tranaplants.10 In 
each of these patient populations, the c1ealDnnc~ values aM 
highly variable. 
In the present stl1dy. a tenfold variation in the clearance 
of cyclosporine was observed in pediatric liver fnplsplant 
patients. The day to day variability In clearance in an 
individual patient has not been assessed and may· have 
contributed in part to this variation. Pediatric patients had a 
higher harmonic lRean cyclosporine clearance per body 
weight as compared with adult liver transplant patients. 
even though they were studied earlier in their course of 
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thctrapy. The highest cyclosporine clearance value (21.5 
mLlmin/lcg) was noted in the youngest study patient (age, 7 
montha). The higher cyciosporine clearance in children Is 
conlisten, with the oblerva~ot1U of bisber clearance per 
body weight of other drugs such' as theophylline in the 
pediatric popula~onll and with our studies of cycJosporine 
in pediatric lddney aod he8rt tranlplant patients.12 Pediatric 
renal transplant patients ru.ve the highest cycl08porine 
blood clearance values. with a harmonic IJ!.lt8n clearance of 
11.8 mLlmin/lcg.l1 The ~her cyc10sp0rine clearance in 
children il consistent with the higher drug doses on a body 
weight buts Uutt are ffequentIy neceslarY' to achieve blood 
concentrations similar to tho-. seen iii adults. 
Studies in bone marrow a~d Jddney ~lant patients 
have shown cOnsidel'lJble variation in the peak plasma 
levels of cyciosporine following oral admlnistratipn of the 
p.rus.1t.15 The ~iMUvailabjgity of cyc~osporin~ has been 
reported to ~nge from 10,., to 50,.". with a m!'aD of 34,. •. 111 
We have observed an ave~ bioavailability of 27.6". in 41 
renal transplant patients in whom a mar~ed variation in the 
bioavailability of cycl08porine ~ also been observed 
(range, <5,." to 89,.,,).8 . 
Because of the limitations in the study design imposed by 
this patient population. the bi08vailabUlty parameters cal-
culated are only estimates of the a~l biolivailabillty 
values. We most likely underestim!lted bioavailability if 
hepatic drug c;~earance had improved on the oral ~v day, 
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Figure 1. CycJosporine blood concentration versua lime in adult 
study potient 16. COncentrations following an introv!lDOUS (e--eJ 
and an oral (x - -xl dose are presented. 
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Figure 2. Cyclosporlne blood concentraiion vetIUI time in pediatric 
study poti!Inf 6. Concentrations following an inllUV!lnous (e--eJ 
and an introv!ll1OUll plus oral (x - - xJ dose are pretenred. 
but may. have overestimated bioavailability if steady state 
had not been achieved at the titne of the intraven0U8 study. 
The vehicle uaed to dilute the c:hiig Huice or milk) wiD not 
however affect drus abeorption.17 Cbangea in drus clear-
ance between the intravenous and oral study would also 
change the bioavailability estimate. 
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In the pediatric orthotopic liver transplantation patients, 
cyclosporine was very poorly absorbed. The bioavailabUity 
ranged from <50/. to 18%. The poor absorption of cyclospo-
riDe in our pediatric orthotopic liver transplantation recipi. 
~nts was predictable from C?ur previous clinical experience. 
However. we did not anticipate such a large variation in the 
absorption in the immedIate postoperative period. This 
observation indit:ates that not all orthotopic liver transplan-
tation patients require prolonged intravenoUs therapy. The 
early initiation of oral eyclosporiDe in conjUnction with the 
intravenous formulation while monitoring trough blbOd 
concentrationS is an effective test of drug absorption. This 
regimen facilitates the early conversion from intravenous to 
oral therapy with cyclosporine in those patients who ade-
quately absorb the drug. 
In contrast with the poor cyclosporine absorption 
observed in our pediatric population in the immediate 
postoperative period, adults with improving liver function 
following orthotopic liver transplantation absorbed 8111. to 
60% of an oral cyclosporine dose. Cyc10sp0rine bi08vail· 
ability has been reported to increase three- to fivefold over 
a three-month time period in renal transplant patients.15 
Improving liver function and bile flow in liver transplant 
recipients may be responsible for improving cyclosporioe 
absorption over time and may permit a dosage reduction. 
Increases in the trough blood concentrations of cyclospo-
rine are particularly notable following T-tube clamping in 
TABLE II 
Cyclolporlne Ph.rmacoklnetlc hrilmeten 
Dole (!!!IL1cc> Clearance Btoavall..,lIIty 
Patient IV Ora' (mLjmlnjq) (9ft) 
1 2.6 8.8 13.0 13 
2 1.8 8.9 12.1 18 
3 2.4 8.1 7.1 <5 
4 1.9 8.1 1.9 <5 
5 3.7 18.3 8.2 <5 
6 2.0 8.4 10.4 19 
78 1.6 9.2 6.0 <5 
7b 2.1 10.4 6.9 <5 
8 3.1 7.0 5.6 <5 
9 2.0 8.6 21.5 8 
10 1.7 9.6 4.9 10 
11 1.8 10.0 6.3 60 
12 0.6 3.4 3.2 29 
13 2.1 3.6 5.3 15 
14 2.0 7.3 7.6 38 
15 1.9 7.3 7.1 8 
16 2.5 7.4 4.4 31 
IV - intravenous. 
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orthotopic liver tranSplantation patien~K11 Previous studies 
have shown this increase is not attributable to increased 
enterohepatic recycling of cyclosporine following T-tube 
clBJIiping.tl Increased bile flow into the gut is mo,st likely 
responsible for the improved cyclosporine absOrption. 
Cyclasporine absorption did not correlate with seriun 
biochemical parameters such as bilirubin or liver enzyme 
levels in the imntediate postoperative period. Gastric emp-
tying and gQt motility were not aasessed, in this Mudy but 
may affect bioaviilability particularly in the immediate 
postoperative period. Estimates of hepatic blood flow were 
likewise not evaluated in this study. Subsequent investiga-
tions in adults with liver disease have demonstrated a good 
correlation between an elevated serum bilirubiit concentra-
tion and a diminished cyclosporine bioavailability follow-
ing an oral dose,zo 
The frequent malabsorption and the marked variability in 
cyclosporine absorption and metabolism makes individual-
izalion of cyclosponne thenlpy essential in individuals 
undergoing orthotopic liver transplantation. CyclotpOrine 
clearance on a body weight basis is high iIi some children 
and necessitates higher than normal doses of the drug based 
on body weight. Only a structured Pf08r8D1 of blood level 
monitoring can presently provide the essential information 
on cycl08porine absorption or metabolism following liver 
transplsn,tation. An adequate monit()ring program should 
include frequent {2-3 times weekly} blood sampling of 
cyclosporine levels during the early postoperative period 
and should recognize the limitations of the assay used.21 
1. Starzl TE. Iwatsukl S. Van Thiel OH. et al: Evolution of liver 
transplantation. Hepatology 1982;2:614-836. , 
z. Caine RY: Recent advances in clinical lransplantallon of the 
liver and pancreas. Tramplant Proc 1983;15:1263-1268. 
a. Caine RY. Williams R. Lindop M. at 81: Improved survival after 
orthotopic liver grafting. 8t Med 11981;283:115-118. 
4. Malatack JJ. ZitelU HI. Gartner IC, at al: Pediatric liver transplan· 
tation under therapy wtth cyclosparin A and steroids. Tramplant 
Proc 1983:15:1292-1298. 
I. Starzl TE. Iwatsukl S. Van Thiel OM. et al: Report of Colorado-
Pittsburgh iiver transplantation studies. Transpiant Proc 1983; 
15:2582-2585. 
651 • J CIIn Ph.-nulCOt 1186;26:147-651 
.. Stam TE. K1intmalm GBG. Porter KA. et al: Livet transplanta-
tion with the use of cYcloapor!n A and prednisone. N Eng.ll Med 
1981:305:266-269. 
7. Sawchuk RI. Cartier LL: Liquid chromatosraphic determination 
of cyclosporln A In blood and plasma, CUn Chem 1981;27:1368-
1371. 
.. Ptachclna1d RI. Venkataramapan R. RlMenthal IT. et aJ: Cynlo-
sporine Idnelics In renal transplantation. CUn Pharmacol Ther 
1935;38:296-303 . 
•• Kennedy MS. Yee Gc, Deeg HI. et al: mharmacoktneti~ and 
toxicity of cycloeporine in DWTOW transplant patients. Tramplant 
Proc 1983;15:2416-2418. 
1 •• Venkataramarts,n R. Burckart GI. Ptachcinakl RI. et a): Cynlo-
sporlne pharmacokinetics In heart transplant pallents. Tl'GlIIIplanl 
Proc (in press). 
11. Miles MV: Pediatric pharmacokinetics, In Munsell DR (ed): 
Applied Clinical Pharmocokinetics. New York, Raven. 1983; 387-
388. 
u. Burckart GI. VenkalaramBnan R. Stam TE. et a1: Cyclosporlna 
clearance In children following orpn transplantation (abstract). 1 
Clln P!wtmacoI1984;24:412. 
13. Ptachcinsld RI. Burckart GI. Rosenthal IT. at al: Cyclosporine 
phannacoldnetlcs In children following cadaveric renal transplan-
tation. Tronsplant Proc (in j:nss). 
14. Beveridge T. Gra.wohl A. Micbot F. et 81: Cyclosporin A: 
pharmacolcinetlcs after a single dose in man and &eNID levela after 
multiple doslns in recipients of allogenic bone marrow grafts. Curr 
Ther Res 1981;30:5-11. 
11. Kahan BD. Ried M. Newbutger I: Pharmacokinetics of cyclo-
.porIne In human renal transplantation. Transplant Proc 1983: 
15:446-453. ' 
lL Wood AI. Maurer G. Nlederberger W. el al: Cyclosporlne: 
pharmacokinetics, metabolism, and drug Interactions. Tramplant 
Proc 1983:15:2409-2412. 
17. Holt OW. Manden IT. lohnston A: Effects of liquid diSpersants 
on the oral absorption of cyclosporlne. TrampIanI Proc (in Pl'8ll). 
lL Ptachcinslci RI. Venkataramanan R. Burckatt G,: Clinical phar-
macolcinetics of cyclosporine. cUn Pharmacokinetics 1988;11:107-
132. 
1'. Venkataramanan R. Starzl TE. Yang S. et al: Bmary excretion 
of cyclospotine in liver transplant patients. Transplanl Proc 
1985:17:286-289. 
ZI. Venkataramanan R. Ptachclnakl RI. 8urcbrt GI. et al: Cyclo-
sparine bi08vailability In liver di8ease (abstract). Drug InteJl CUn 
Phorm 1985:19:451. 
21. Burckart G. Starzl T. Williams L. et al: Cynlosporine monitoring 
~nd pharmacokinetics in pediatric liver transplant patients. Trans-
planl Proc 1985;17:1172-1175. 
OownlOOOe(llrom http://WW' ..... icbnpham.orgat iJNIV uf- r'l r13SUrl.DH 01' Af/fll C!8, £008 
@)1986 ArMriean Cnuege of Clinir.81 PhIll'n'laCOlogy, All rights I'ItSRrvad. Not for colT'mRrciat OM: or unauthorized distributkln. 
